Novo Nordisk

It may be time to speak with your doctor about your hemophilia management.

Still worried about breakthrough bleeds?

If you live with hemophilia A and still experience breakthrough bleeds, you’re not alone. A recent survey found that half of respondents treated using extended half-life medications had one or more bleeds within a year.^a

But here’s something to remember:

Any bleed you have is worth speaking up about

Get informed

^aFrom July 2023 to February 2024, people with hemophilia A and their doctors took a survey about managing hemophilia and the challenges with current treatment. In total, 62 doctors and 348 patients with hemophilia A completed the survey. Among the patients with bleeding data of more than 1 year, 28 were using EHL treatment, and 40 were using SHL treatment. This study only included patients receiving hemophilia care, which may not reflect the full range of patient experiences, and since it looks at data from a single point in time, we are unable to observe how health conditions might change over time.

Every bleed matters—
especially joint bleeds.

51% of those who live with hemophilia A reported one or more spontaneous bleeds during 18 months of follow-up, according to a study of 70 people on non-factor therapy that works like factor 8. Of those, 80% were joint bleeds, which can lead to joint damage, long-term pain, and reduced mobility.^b

Are you reporting all your bleeds?

^bIn a study conducted by the Israeli National Hemophilia Center, 70 people with hemophilia A who had received prophylactic factor 8 mimetic therapy. The study analyzed the number of spontaneous and traumatic bleeds over an 18-month follow-up period.

Report your bleeds. Every one of them.

Is your treatment helping you to prevent bleeds? Take charge of your hemophilia A care by reporting all your bleeds and informing your doctor about your management challenges. Here’s a way to start.

See the discussion guide

Stay in the know

Don’t miss out on the latest hemophilia updates and resources from Novo Nordisk.

Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579.